Conclusions: These findings establish the MAZ/SETD1B/CD24 signaling cascade as a critical regulatory mechanism of LCSC stemness and highlight Trip as a potential therapeutic agent for HCC. The gene discussed is CD24; the disease is hepatocellular carcinoma.